Monte Rosa Therapeutics Inc (GLUE NASDAQ) stock market data APIs
$23.265
-1.54(-6.6%)
as of January 7, 2026
Try our APIs with
free plan!
Monte Rosa Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Prev. Close
23.265
Open
21.7215
High
25.2238
Low
21.2275
52 wk Range
3.5001-25.15
Market Cap
1 516 M
P/E Ratio
72.75
Shares Outstanding
65 118 K
Revenue
182 M
EPS
-0.33
Beta
1.605
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Monte Rosa Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Monte Rosa Therapeutics Inc data using free add-ons & libraries
Get Monte Rosa Therapeutics Inc Fundamental Data
Monte Rosa Therapeutics Inc Fundamental data includes:
- Net Revenue: 182 M
- EBITDA: 16 840 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monte Rosa Therapeutics Inc News
New
Monte Rosa Therapeutics Reaches Analyst Target Price
In recent trading, shares of Monte Rosa Therapeutics Inc (Symbol: GLUE) have crossed above the average analyst 12-month target price of $22.70, changing hands for $23.23/share. When a stock reaches t...
Stocks Settle Mostly Lower as Early Rally Fades
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.34%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.94%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.06%. March E...
Top Midday Gainers
Monte Rosa Therapeutics (GLUE) said Wednesday early trial results of its drug candidate, MRT-8102, s PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Stocks Hover Near Record Highs on Mixed US Economic News
The S&P 500 Index ($SPX) (SPY) today is up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.36%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.34%. March E-mini S&P futures (ES...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
